Building the next generation of biotech ventures

Welcome to BaseLaunch

We partner with scientists and entrepreneurs to help launch and grow exceptional biotech ventures developing cutting-edge therapeutics. And we know how to do this – so far our portfolio has raised over $1 billion in financing.

Money dollar Icon png

Up to $500,000
in financing

Access to our partners,
global biopharma & investors

Company & team
build out

Access to labs &
related infrastructure
where needed

Partners

We are very pleased to continue our commitment to BaseLaunch. Basel has always been home to great ideas and innovation and today it is a leading life sciences hub within Switzerland and globally.

James SabryGlobal Head of Roche Pharma Partnering

We are delighted to join BaseLaunch as a partner in the next phase of its company building activities. The Pureos team worked closely with BaseLaunch during the Series A funding of Alentis Therapeutics and has been very impressed by the team and the quality of the selected programs.

Klaus Breiner, PhDManaging Partner at Pureos Bioventures

This partnership will help us identify and build relationships with potential external collaborators from throughout Europe…

Dr. Adrian ZuercherVice President, Research Europe and Head of Plasma Protein Research, CSL Behring

Incubators and accelerators are central to the global healthcare start-up ecosystem. We have been collaborating with BaseLaunch since launch in supporting the growth and development of early-stage biotech ventures and recognize the contribution the team has made towards achieving their goals...

Nerida ScottHead, Johnson & Johnson Innovation

With our involvement in the review process and funding decisions through our investment board seat, we aim to contribute to BaseLaunch‘s company creation track record and leverage AbbVie‘s expertise in translating innovative science into novel therapeutics.

Christian SchubertVice President and Head of AbbVie Ventures, Cambridge, MA

Our partnership with BaseLaunch strengthens our connection to European biotech innovation. By joining the investment board, we can help guide company creation and apply Takeda’s expertise in turning science into new therapies. We look forward to participating in BaseLaunch and advancing innovative medicines together.

Alison HandleyHead of the Center for External Innovation at Takeda

Latest news

Takeda becomes a BaseLaunch partner

Takeda becomes a BaseLaunch partner

Basel, Switzerland - December 16, 2025 — BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has…
Aukera Therapeutics Comes Out of Stealth

Aukera Therapeutics Comes Out of Stealth

Basel, Switzerland - 11 December 2025, Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters…
Gibela Publishes New Findings on CNNM4 in Metabolic Disease

Gibela Publishes New Findings on CNNM4 in Metabolic Disease

Basel, Switzerland - 14 November 2025, Gibela Therapeutics GmbH (“Gibela”), the Basel-based Biotech focusing on the treatment of liver diseases using siRNA technology to target…
Tolremo Announces Positive TT125-802 Results at ESMO 2025

Tolremo Announces Positive TT125-802 Results at ESMO 2025

Basel, Switzerland - October 17, 2025, TOLREMO therapeutics AG (TOLREMO) today announced encouraging clinical data from 34 patients with advanced solid tumors treated with TT125-802…
Alentis appoints Dr. Mark Pruzanski as CEO

Alentis appoints Dr. Mark Pruzanski as CEO

Basel, Switzerland – Oct 15, 2025, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology…
Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…

Application cycle is now open!

The next deadline is 7th of January 2026